Parkinson's Disease Causes
Parkinson's Disease Causes
Two things about the mechanism of Parkinson's disease are established. The nerve cells that make dopamine, in a small region of the brainstem, die; and inside the cells that remain, a protein that normally helps traffic between nerve terminals misfolds and accumulates. Why those particular cells die, and why they die in one person and not another, is not established, and any account that presents a single cause is simplifying. What can be described honestly is a shape: age doing most of the work, genes loading the gun in a minority, and environmental exposures adding risk in ways that are consistent enough to act on and imprecise enough not to blame.
The mechanism: what is actually happening
The cells that are lost sit in the substantia nigra and send dopamine into the striatum, where it is one of the signals that permits movement to begin. Their loss is gradual and asymmetric, which is why one side is affected first. By the time slowness is noticeable, a substantial proportion are already gone.
The second established finding is the protein: alpha-synuclein, which helps traffic at the nerve terminal, misfolds and accumulates. The aggregates are what a pathologist sees as Lewy bodies, and the condition belongs to the synucleinopathies.
One observation has reorganised the early years: the protein and the non-motor features appear in the olfactory bulb and in the gut before they appear in the substantia nigra. This is the basis for the proposal that the process may begin outside the brain and ascend. It has real support and it is not settled.
Genes: real, important in a minority, rarely the whole story
Most people have no identifiable single genetic cause. A minority have an affected first-degree relative, and a smaller minority — more of them diagnosed young — carry a variant that substantially explains it.
Where a variant is found, the ones most often involved are LRRK2, the commonest dominant form; PRKN and PINK1, which produce onset decades earlier and a slower course; SNCA; and GBA1, the most common genetic risk factor overall and one associated with earlier onset and more cognitive change.
It does not change today's treatment: a person with a LRRK2 variant is treated the same way as one without. What it does is answer why this happened at 42 rather than 72, what the likely course is, what it means for children and siblings, and whether a trial is open. It is offered with counselling rather than sold.
Environmental exposures: the associations that hold up
Several exposures are consistent enough across studies to take seriously, and none is a cause in the sense that removing it would prevent the condition in a given person. Certain pesticides, notably paraquat and rotenone, carry the strongest signal, more with prolonged occupational exposure; trichloroethylene, a degreasing solvent, has a substantial body of evidence; welding and manganese and carbon monoxide produce parkinsonism directly rather than through the degenerative process.
Head injury is reported repeatedly as a risk factor, with the association strongest for injuries causing loss of consciousness and for repeated ones. The relationship is consistent across studies and it remains difficult to separate from the other things that travel with contact sport and with manual work, which is why it is described as an association rather than established as a cause.
Three run the other way. Higher caffeine consumption and lifelong physical activity are associated with a lower rate. Smoking is too — and this needs saying carefully: that smokers are diagnosed less often is a fact about epidemiology and not a recommendation; the mechanism is not established and the harms of smoking are not in question.
Age, and why it dominates everything else
Age is the largest risk factor by a wide margin. Prevalence rises steeply after 60, where the international literature commonly quotes roughly 1 in 100; it is uncommon before 50, where it is called young-onset disease and accounts for around 1 in 10 of diagnoses. Men are affected somewhat more often than women.
Age dominates for the same reason nothing has been shown to slow the condition: the systems that keep a neuron healthy — protein handling, mitochondrial energy, clearance of damaged components, control of inflammation — become less reliable with time, and this cell population is among the most demanding and least able to compensate.
Two consequences follow. A diagnosis at 80 and one at 45 are not the same conversation: the younger person has decades ahead, develops fluctuations earlier, and faces work, driving and family decisions. And things attributed to ageing — a slowing gait, a quieter voice, a stoop — are sometimes this condition, which matters because the treatments work.
The things that are not true
It is not contagious, and it cannot be caught. It is not caused by mobile phones, by stress, by overworking the brain or by thinking too hard. It is not the same as Alzheimer's disease or as dementia generally: it is a condition of movement with cognitive involvement in a substantial minority, and conflating them leads people to expect memory loss first.
It is not a fast disease by default. The course runs for decades for most people, and the two things that shorten a life with it — pneumonia from swallowing problems and injury from falls — are both addressed rather than accepted. It is not caused by a food, a supplement, a vaccine or a medication taken years ago.
And two in the other direction. A tremor is not the disease, and a person who does not tremble still has it. A person who looks well is not necessarily well: the flat expression and the quiet voice are part of the condition rather than a mood, and the most disabling features of a day are frequently the ones nobody can see.
Risk is not destiny, and prediction is not yet possible
Everything here is a statement about populations. For an individual, a risk factor does not mean the condition will come and its absence does not mean it will not. Most people with an affected relative never develop it, and most people who develop it have none of the named exposures.
Prediction in an individual is an open research question rather than a clinical service. The strongest known predictor is REM sleep behaviour disorder in an older adult, a large proportion of whom eventually develop a synucleinopathy. Alongside it, subtle motor findings, smell testing, imaging and assays for misfolded alpha-synuclein are being evaluated. None is yet a reason to tell an asymptomatic person their future.
There is no lever that prevents the condition. There are several that change what the years with it look like: being diagnosed correctly and early rather than late; exercise maintained rather than attempted; treatment timed against a life rather than a stage; and a device asked about while it is still available.
Where the research stands, and what it means for you
The most active research area is the one that has delivered least: something that changes the course rather than the symptoms. Trials are underway on agents directed at alpha-synuclein, on the clearance systems that dispose of it, on the GBA1 pathway and on brain inflammation. Some are in people with a defined variant. None is established or available as treatment.
The second area is diagnosis before symptoms, using seed-amplification assays for misfolded alpha-synuclein, imaging, and digital measures from wearables.
What this means now is practical. Ask whether any trial is open to you and whether a genetic result would change your eligibility. Ask whether your centre follows a defined pathway rather than reacting visit by visit. And treat what is established — exercise, timing, swallowing, falls, the device window — as the plan, because those are the things that work today.